Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247170 | 1.00 | AHR (0.54) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL6435102 | 0.95 | AHR (0.53) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL6434844 | 0.95 | AHR (0.53) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL6434839 | 0.95 | AHR (0.53) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL17682006 | 0.93 | CNR1 (0.54) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL2005561 | 0.93 | CNR1 (0.54) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL19452377 | 0.93 | CNR1 (0.54) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL15688436 | 0.93 | CNR1 (0.54) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL2005564 | 0.93 | CNR1 (0.54) | AHRKDM4ECYP3A4LMNATP53 | |
| SCHEMBL19667752 | 0.93 | CNR1 (0.54) | AHRKDM4ECYP3A4LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014073003-A1 | SINGLE-STEP PROCESS FOR THE PREPARATION OF ARYL OLEFINS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-05-15 | — | — | WO | claimed |
| WO-2014073003-A1 | SINGLE-STEP PROCESS FOR THE PREPARATION OF ARYL OLEFINS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014073003-A1 | SINGLE-STEP PROCESS FOR THE PREPARATION OF ARYL OLEFINS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-05-15 | — | — | WO | disclosed |
| EP-1799627-B1 | IRON OR COBALT-CATALYZED CARBON-CARBON COUPLING REACTION OF ARYLS, ALKENES AND ALKINES WITH COPPER REAGENTS | SALTIGO GMBH (DE) | 2010-05-05 | — | — | EP | disclosed |
| EP-1799627-B1 | IRON OR COBALT-CATALYZED CARBON-CARBON COUPLING REACTION OF ARYLS, ALKENES AND ALKINES WITH COPPER REAGENTS | SALTIGO GMBH (DE) | 2010-05-05 | — | — | EP | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1453913-A4 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1453913-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | Antex Pharma, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003062443-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-0532621-A1 | AMIDE LINKED PYRIDYLE-BENZOIC ACID DERIVATIVES FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991018883-A1 | AMIDE LINKED PYRIDYLE-BENZOIC ACID DERIVATIVES FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SLC39A14, MAL2, AHR | AHR 3/4885KDM4E 2249/4885CYP3A4 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.